1. Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. (13th June 2016) Authors: Lentz, S. R.; Cerqueira, M.; Janic, D.; Kempton, C.; Matytsina, I.; Misgav, M.; Oldenburg, J.; Ozelo, M.; Recht, M.; Rosholm, A.; Savic, A.; Suzuki, T.; Tiede, A.; Santagostino, E. Journal: Haemophilia Issue: Volume 22:Number 5(2016:Sep.) Page Start: e445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. (8th May 2013) Authors: Kulkarni, R.; Karim, F. A.; Glamocanin, S.; Janic, D.; Vdovin, V.; Ozelo, M.; Rageliene, L.; Carboni, E.; Laguna, P.; Dobaczewski, G.; Seremetis, S.; Lindblom, A.; Santagostino, E. Journal: Haemophilia Issue: Volume 19:Number 5(2013:Sep.) Page Start: 698 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗